How a Stem Cell Transplant Donor Is Chosen: HLA Typing and Matching Explained

Key Takeaways
- HLA typing reads a small set of highly variable immune genes on chromosome 6, and it, not blood group, decides whether someone can donate stem cells.
- Because HLA genes are inherited as blocks, each full sibling has roughly a 25% chance of matching fully and a 50% chance of being a half-match.
- An 8/8 match covers both copies of HLA-A, -B, -C and -DRB1; adding DQB1 makes it 10/10, and modern typing is done at high resolution.
- The chance of finding a fully matched unrelated donor varies with ancestry, from around 75% for some groups to under 20% for others in US registry analyses.
- Half-matched (haploidentical) transplants from parents, children or siblings are now an established alternative when no full match exists, thanks to newer GVHD-prevention strategies.
- Liver transplants are allocated mainly by blood group, size and urgency rather than HLA, whereas stem cell transplants depend on HLA because the graft is an entire immune system.
A stem cell transplant donor is chosen mainly by HLA typing, a genetic test that reads the human leukocyte antigen markers on a person's cells. Doctors compare the patient's HLA genes with those of siblings, registry volunteers or cord blood units and prefer the closest match, because mismatched HLA raises the risk of rejection and graft-versus-host disease. The transplant team makes the final choice.
The envelope arrives with a long swab inside and a two-line instruction sheet: rub the inside of your cheek, seal, mail back. For a sister who has just learned that her brother’s leukemia will need a donor, that swab feels absurdly small for the job it is being asked to do.
What it carries is enough DNA to read a handful of genes on chromosome 6, the ones that write the “ID badge” every cell wears. This is HLA typing for a stem cell transplant, and it decides more about who can donate than age, blood group or how closely two people resemble each other.
This explainer walks through what those genes do, why a brother or sister has roughly a one-in-four chance of matching, how a half-match or a stranger on a registry can step in, and what the weeks after a match usually look like. The decisions along the way belong to the transplant team; the goal here is that you understand them.
What is HLA typing, and what actually happens in a stem cell transplant?
Human leukocyte antigens (HLA) are proteins that sit on the surface of most cells and show the immune system small fragments of whatever is inside the cell. Think of them as a display case: a healthy cell displays ordinary pieces of itself, an infected or cancerous cell displays something odd, and patrolling T cells (a type of white blood cell) decide whether to attack.
The catch is that the display case itself varies enormously from person to person. The HLA genes are among the most variable in the human genome, with thousands of known versions. Your immune system learns early in life which HLA versions count as “self.” Anything else reads as foreign.
A stem cell transplant replaces a patient’s blood-forming system with new blood stem cells, usually after chemotherapy or radiation has cleared space in the bone marrow. When those cells come from another person (an allogeneic transplant), two immune systems meet. The patient’s remaining immune cells may attack the graft, and the donor’s T cells, arriving with the graft, may attack the patient. The second problem is called graft-versus-host disease (GVHD), and it is the main reason matching matters.
HLA typing stem cell transplant work therefore has one aim: find a donor whose display case looks as close as possible to the patient’s own. The test reads the DNA sequence of specific HLA genes from a cheek swab or blood sample, as MedlinePlus describes, and reports each version found. A sibling’s sample, a registry volunteer’s stored profile or a cord blood unit is then lined up against the patient’s result, gene by gene.
Matching does not make a transplant risk-free. It lowers the odds of the two most serious immune complications and widens the margin in which the care team can manage everything else.
HLA typing vs blood typing: why a matching blood group is not enough
Families often assume that because a brother shares the patient’s O-negative blood, he must be the donor. The two tests measure different things, and for stem cells the HLA result is the one that counts.

Blood typing looks at ABO and Rh antigens on red blood cells. Red cells have no nucleus, carry almost no HLA, and are matched for transfusion by ABO and Rh alone. HLA typing looks at genes expressed on white cells and nearly all nucleated tissue, which is where the immune system does its checking.
Because of that, a stem cell donor and recipient do not need the same blood group. The NHS notes that the donor’s blood type can differ, and after a successful transplant the patient’s blood group gradually becomes the donor’s, since the new marrow is now producing the red cells. Transplant teams plan around an ABO mismatch with laboratory steps and transfusion protocols; it is a logistical issue, not a barrier.
The reverse is also true: sharing a blood group says nothing about HLA. Two strangers with type A blood are no more likely to be HLA-matched than any other pair.
A quick way to hold the distinction:
- Blood typing: a few antigens, a result in minutes, used for transfusions and partly for solid organs.
- HLA typing: several highly variable genes read by DNA sequencing, days to weeks for a full result, used for stem cell and some organ transplants.
Nurses on transplant units spend a surprising amount of time untangling this confusion at the bedside. If a relative has already been told their blood group “doesn’t match,” they may still be the best HLA candidate in the family. The care team can clarify which test has actually been done.
Which HLA genes are tested, and what does an 8/8 or 10/10 match mean?
Laboratories focus on a small set of HLA genes that carry the most weight in transplant outcomes. Each person has two copies of every gene, one inherited from each parent, so each gene contributes two “points” to the score.
| Gene | HLA class | Typically included in |
|---|---|---|
| HLA-A | Class I | 8/8 and 10/10 scores |
| HLA-B | Class I | 8/8 and 10/10 scores |
| HLA-C | Class I | 8/8 and 10/10 scores |
| HLA-DRB1 | Class II | 8/8 and 10/10 scores |
| HLA-DQB1 | Class II | 10/10 scores |
| HLA-DPB1 | Class II | Extended typing, used to rank similar donors |
An “8/8 match” means both copies of HLA-A, -B, -C and -DRB1 are identical between donor and recipient. A “10/10 match” adds both copies of DQB1. Some centers also look at DPB1 when deciding between several otherwise equal donors.
Resolution matters as much as the gene list. Low-resolution typing identifies the broad family a gene version belongs to; high-resolution typing reads the exact sequence down to single-letter differences. Two people can look matched at low resolution and turn out mismatched at high resolution. Modern transplant typing is done at high resolution for this reason.
A single mismatch (7/8) is not automatically disqualifying. Studies summarized in NIH-indexed literature show that each mismatch adds risk, but a 7/8 unrelated donor may still be a reasonable option when no better one exists and the disease cannot wait. Which mismatches are better tolerated, and in which direction, is a technical judgment the transplant physician makes with the HLA laboratory.
Why a brother or sister has about a 1-in-4 chance of being a full match
The HLA genes sit close together on chromosome 6 and are almost always inherited as a block, called a haplotype. Each parent has two haplotypes and passes one, at random, to each child.

Picture a mother with haplotypes M1 and M2 and a father with F1 and F2. Every child receives one M and one F, so there are four possible combinations: M1F1, M1F2, M2F1, M2F2. A sibling matches the patient fully only when both haplotypes are the same, which happens in one of those four combinations. That is the roughly 25% figure that the National Cancer Institute and Mayo Clinic quote for full sibling matches.
The same arithmetic produces two other useful facts. A sibling has a 50% chance of sharing exactly one haplotype, making them a half-match. And a sibling has a 25% chance of sharing neither.
Parents and biological children are a different case. A child always receives exactly one haplotype from each parent, so parent and child are reliably half-matched and almost never fully matched. Grandparents, aunts, uncles and cousins share haplotypes less predictably and are usually typed only when closer relatives are unavailable.
Identical twins are the special exception. They share all HLA genes, so the match is perfect, but the graft also carries no immune “foreignness” against the disease. For some cancers, teams weigh that lost graft-versus-tumor effect, in which donor immune cells help control residual malignant cells, when deciding whether a twin is the best donor.
In practice, most patients do not have a matched sibling. Smaller family sizes make this more common, which is why registries and alternative donors have become central to HLA typing stem cell transplant planning rather than a fallback.
Half match stem cell transplant: how haploidentical donors changed the search
A haploidentical transplant uses a donor who shares one of the patient’s two HLA haplotypes, meaning roughly half the HLA genes match. Parents, children and about half of siblings qualify automatically, which means almost everyone has at least one potential half-matched relative.
For decades this option was limited by severe GVHD and high rates of graft failure. What changed was the approach to immune suppression after the transplant. One widely used strategy gives a chemotherapy drug of the alkylating class (post-transplant cyclophosphamide) in the days after the cells are infused, timed to remove the donor T cells that are actively dividing in response to the patient’s tissues while sparing the quieter cells needed for recovery. Other centers remove specific T-cell subsets from the graft in the laboratory before infusion.
Guideline-level reviews indexed in PubMed describe half-matched transplants as an established alternative when no fully matched donor is available, with complication rates that are now closer to those of matched unrelated donors than they once were. How the options compare for a specific disease, age and health status is a judgment the transplant physician makes; the evidence does not support calling one approach universally better.
Practical advantages are real. A relative can usually be typed and cleared quickly, which matters when the disease is aggressive. The donor is often available again later if additional cells are needed.
Trade-offs exist too. Immune recovery after a half-matched graft can be slower, infections in the first months need close attention, and the medicines used to prevent GVHD carry their own side effects. Deciding between a 7/8 unrelated donor, a half-matched relative and a cord blood unit is one of the more nuanced calls in transplant medicine, and it is made case by case.
HLA matching for bone marrow transplant through registries and cord blood
When no suitable relative exists, the search moves to volunteer registries. Millions of adults worldwide have been HLA-typed and have agreed to donate if called. The transplant center submits the patient’s high-resolution typing, and the registry returns a ranked list of potential matches, often within days, with full confirmatory typing of the best candidates taking longer.
The likelihood of finding a fully matched unrelated donor depends heavily on ancestry, because HLA versions cluster in populations. A large analysis of the United States registry published in a NIH-indexed journal estimated that the chance of an 8/8 matched adult donor was around 75% for patients of white European background and under 20% for patients of Black or African American background, with other groups in between. Mixed ancestry lowers the odds further because rarer combinations of haplotypes are less likely to appear in any registry.
Umbilical cord blood offers a second route. Cord blood units are collected at birth, frozen and stored in public banks. Because the immune cells in cord blood are immature, a greater degree of HLA mismatch is tolerated, and matching is typically assessed at fewer loci. The limitation is cell dose: a single unit contains a fixed number of stem cells, which is why cord blood is used more often for children and smaller adults, or as two combined units.
Several factors beyond HLA help rank donors who score the same:
- Age, since registries and guidelines favor younger adult donors.
- Cytomegalovirus (CMV) status, a common virus whose match status affects infection risk after transplant.
- Donor sex and prior pregnancies, which influence certain immune complications.
- Availability, health screening results and willingness to donate the requested cell source.
The HLA laboratory and transplant physician weigh these together; no single factor decides.
What cell types express HLA, and why mismatch leads to rejection or GVHD
People searching “what cell types express HLA” are often trying to understand why red blood cells can be transfused freely while marrow cannot. The answer lies in the two classes of HLA.
Class I molecules (HLA-A, -B, -C) are expressed on nearly every nucleated cell in the body: skin, liver, gut lining, lung, kidney, and all white blood cells. Mature red blood cells and platelets carry little or none, which is why ABO and Rh, not HLA, govern routine transfusion.
Class II molecules (HLA-DR, -DQ, -DP) are expressed mainly on professional antigen-presenting cells: dendritic cells, B cells, macrophages and some activated T cells. These are the cells that formally introduce a foreign fragment to the immune system and trigger a coordinated response. Under inflammation, other cell types can be induced to display class II as well.
Now follow the biology of a transplant. The patient’s surviving immune cells encounter donor stem cells whose class I and II molecules look foreign; if enough of those cells remain, they may reject the graft. The donor’s T cells, arriving with the graft, survey the patient’s body and find foreign HLA on skin, gut and liver, precisely the organs most affected by acute GVHD. The rash, diarrhea and jaundice that characterize GVHD are the visible signature of where class I is densest and most exposed.
Close HLA matching reduces, but does not eliminate, these reactions, because many minor histocompatibility antigens outside the HLA genes also differ between any two unrelated people. This is why even fully matched transplants require medicines that suppress or modulate the immune system for months afterward, and why the transplant team tracks blood counts, skin, gut and liver function so closely during that period.
What the HLA test involves for the patient, the family and a volunteer
The sample itself is undramatic. Most registries use a cheek swab mailed from home; transplant centers usually draw a small tube of blood from the patient and from family members, as MedlinePlus describes. No fasting, no preparation, no recovery.
Behind the scenes, the laboratory extracts DNA and sequences the HLA genes. Early screening may use lower-resolution methods to narrow a long list; the final candidates then receive high-resolution confirmatory typing, often on a freshly collected sample to rule out labeling errors. Patients are typically typed twice, on separate samples, for the same reason.
Timing varies with the method and laboratory workload. Registry preliminary results often return in days, while full confirmatory typing of a selected donor can take longer; the transplant coordinator can give a realistic estimate for a specific case.
A frequent question is cost. HLA typing for a patient and immediate family is normally arranged and billed through the transplant program, and volunteer registry typing is usually free to the donor. Coverage rules differ by insurer and country, and the financial counselor or coordinator attached to the program is the right person to ask; no general figure would be accurate.
Family members sometimes worry the test will reveal other health information. Standard HLA typing reports only the HLA genes. Certain HLA versions are associated with conditions such as celiac disease or ankylosing spondylitis, but a transplant typing report is not a diagnostic test for those, and results are not routinely shared outside the transplant team.
One more practical point: being typed does not obligate anyone to donate. A matched relative or volunteer goes on to a full medical screening and a separate informed consent discussion before any collection is scheduled.
Who is usually a candidate for a donor stem cell transplant, and who is often asked to wait
HLA typing happens only after a transplant physician decides a donor transplant is a reasonable path. That earlier decision is shaped by the disease and by the patient’s overall fitness.
Allogeneic transplant is most often considered for cancers that start in the blood or bone marrow, such as acute leukemias, certain lymphomas, myelodysplastic syndromes and myeloma, as well as non-cancer conditions including severe aplastic anemia, some inherited immune deficiencies and hemoglobin disorders. Mayo Clinic and the National Cancer Institute list these as the main indications.
Fitness assessment is thorough: heart, lung, liver and kidney function tests, infection screening, a review of previous treatments and a measure of how well the patient manages daily activities. Chronological age alone is less decisive than it once was; many centers transplant people in their sixties and seventies when organ function allows, often using reduced-intensity conditioning.
Situations where a team typically asks a patient to wait, or recommends another approach, include:
- Active, uncontrolled infection, which must be treated first because conditioning removes the immune system.
- Disease that is not yet in remission or adequately controlled, since transplant works best against a small residual burden.
- Organ function that would not tolerate conditioning, such as significant heart or lung impairment.
- Lack of a suitable donor at that moment, in which case the search continues while other treatment proceeds.
- A support situation that cannot yet sustain the months of close follow-up and caregiving the transplant requires.
“Wait” is rarely “never.” Infections resolve, remissions deepen, registries grow and new half-matched relatives can be typed. The decision is revisited by the multidisciplinary team, and a second opinion from another transplant physician is a normal part of the process rather than a sign of distrust.
Does a liver transplant need HLA typing? How stem cell matching differs from organ matching
This comes up because families often have experience with one kind of transplant and assume the rules carry over. They do not, and the differences are instructive.
For stem cell transplants, HLA is the dominant criterion because the graft is an entire immune system that will live inside the patient and judge every tissue it meets. Blood group is secondary.
For solid organs, the priorities shift. Kidney transplantation uses HLA matching alongside ABO compatibility, and the patient is also tested for pre-formed antibodies against donor HLA, since those can trigger rapid rejection. Better HLA matching is associated with longer kidney graft survival, though modern immunosuppression has narrowed the gap, and organs are routinely allocated across some degree of mismatch.
Liver transplantation is the clearest contrast. Livers are allocated mainly on blood group compatibility, size match and medical urgency. Routine HLA matching is not required, partly because the liver is relatively tolerant of immune attack and partly because the shortage of donor livers makes waiting for an HLA match impractical. Antibody screening may still be performed in specific circumstances. Heart and lung allocation similarly rely more on ABO, size and urgency than on HLA.
Why the difference? A transplanted liver is tissue that the recipient’s immune system must learn to tolerate, and immunosuppressive medicines manage that one-directional problem. A stem cell graft creates a two-directional problem: the graft can be rejected, and the graft can attack. HLA matching addresses both at once, which is why it carries far more weight.
If a relative has previously been typed for a kidney donation, that result may still be useful for a stem cell search, but the transplant center will usually repeat typing at high resolution before relying on it.
How donors are ranked when several HLA matches are available
Finding more than one acceptable match is a good problem, and it is increasingly common for patients with well-represented ancestry. The team then applies a second layer of criteria, most of which are about the donor’s biology and practical availability rather than anything the patient can influence.
Donor age is usually the first tiebreaker. Registry data summarized by the NHS and by NIH-indexed reviews consistently link younger donor age with better recipient outcomes, likely reflecting the quality and reserve of younger stem cells. This is why most registries recruit new volunteers in early adulthood and why a younger unrelated donor is sometimes preferred over an older matched sibling.
CMV status comes next. Cytomegalovirus is a common herpes-family virus that stays dormant for life. When the patient has never been exposed, a CMV-negative donor is generally preferred to avoid introducing it; when the patient is already positive, a positive donor may bring useful immunity. Teams interpret this alongside the antiviral strategies available.
Other considerations the transplant physician may weigh:
- Donor sex and, for female donors, number of pregnancies, which can prime the immune system against certain minor antigens.
- ABO compatibility, manageable in any case but simpler when matched.
- Donor weight relative to the patient, which affects whether enough cells can be collected.
- Whether the donor is willing and medically able to give the preferred cell source, peripheral blood or marrow.
- Geography and logistics, since collected cells must reach the patient within a limited window.
None of these overrides HLA. A younger, CMV-matched 7/8 donor is not automatically chosen over an older 8/8 donor; the physician integrates everything, and the reasoning should be explained to the patient in plain language. Asking for that explanation is entirely reasonable.
What the following weeks usually look like once a donor is confirmed
A confirmed match sets two timelines moving in parallel, and both are coordinated by the transplant program so that cells arrive on the day the patient is ready.
On the donor side, a full medical examination, infection screening and informed consent come first. If peripheral blood stem cells are requested, the donor receives daily injections of a growth factor for several days before collection to move stem cells from the marrow into the bloodstream, as the NHS describes; the collection itself is done by apheresis, where blood is drawn, stem cells are separated and the rest is returned, over a session lasting a few hours, sometimes repeated the next day. If bone marrow is requested, the donor has a short procedure under general or regional anesthesia in which marrow is withdrawn from the back of the pelvis. Most donors are home the same or next day and describe aching, fatigue or bruising that settles over days to a couple of weeks.
On the patient side, the days before infusion are the conditioning phase: chemotherapy, sometimes with radiation, intended to clear diseased cells and make room for the graft. The infusion itself resembles a blood transfusion through a central line.
Then comes the wait for engraftment, the point when the new marrow begins producing blood cells. Mayo Clinic and the National Cancer Institute describe this as typically taking a few weeks, during which the patient has very low blood counts, needs transfusions and infection precautions, and is watched closely for early GVHD. Full immune recovery is measured in months, with vaccinations usually repeated later.
The transplant coordinator will supply a written calendar for a specific case. Treat any numbers above as typical ranges from published sources, not as a schedule.
What people often get wrong about HLA typing and donor matching
Myths around donation deter volunteers and frustrate families. A few corrections, each grounded in mainstream guidance.
“My blood type matches, so I’ll be the donor.” Blood group is not the matching test. HLA genes decide, and sharing a blood group gives no information about them.
“Parents are the best match.” Parents are reliably half-matched, which is useful, but they are almost never fully matched. Siblings are the only relatives with a realistic chance of a full match.
“Donating means surgery on the spine.” Marrow is collected from the pelvis, not the spine, and most donations today are peripheral blood stem cells collected through a vein. The NHS and Mayo Clinic describe both methods as outpatient or short-stay procedures.
“A perfect match guarantees no GVHD.” Minor antigens outside the HLA genes differ between any two people, so GVHD can occur even with a 10/10 match. Matching lowers the risk; it does not remove it.
“Registry typing reveals my whole genetic health profile.” Standard HLA typing reads a small set of immune genes. It is not a general genetic test and is not used to diagnose other conditions.
“If no full match exists, there is no transplant.” Half-matched relatives, single-mismatch unrelated donors and cord blood are all established routes. Which is best depends on the disease and the patient’s circumstances, and it is the team’s call.
“Being typed commits me to donating.” Typing is a screening step. Donation follows a separate medical evaluation and consent, and a volunteer may withdraw, although registries ask people to decide early because patients begin conditioning in reliance on a committed donor.
“Younger patients always get priority.” Donor age matters; patient age is weighed with fitness and disease, not used as a cutoff on its own.
Questions to ask your care team about HLA typing and donor choice
A transplant consultation covers a great deal, and families often leave with questions they wish they had asked. Taking a short list, and a second person to take notes, helps. These questions are specific to the matching process and worth raising directly.
- Which HLA genes were typed, and at what resolution? Will the patient be typed again on a second sample?
- Which relatives should be typed first, and how will they be contacted and tested?
- If a sibling is a half-match, how does that option compare here with a matched unrelated donor or cord blood for this diagnosis?
- How likely is a full unrelated match given the patient’s ancestry, and how long is the search expected to take?
- If several donors match, what tiebreakers will you use, and will you walk us through the final ranking?
- Is a single HLA mismatch acceptable in this case, and which mismatches do you consider better tolerated?
- What cell source do you prefer, peripheral blood or marrow, and why for this disease?
- How will the donor be protected, and who looks after the donor’s interests separately from the patient’s?
- What is the plan if the preferred donor becomes unavailable close to the transplant date?
- How will ABO or CMV mismatch be managed if it is present?
- What GVHD prevention approach is planned, and what are its main side effects?
- Who do we contact between visits with questions about the search?
Expect honest, sometimes qualified answers. A physician who says “the evidence is mixed on that” or “it depends on how the disease responds to the next cycle” is describing the real state of knowledge, not evading. Where the team’s recommendation differs from something read online, ask them to explain the difference; the published literature changes, and a center’s protocol reflects its own experience and the current guidelines it follows.
When to call your doctor during the donor search and after transplant
The donor search itself produces no physical symptoms, but the disease being treated and the therapy bridging the patient to transplant certainly can. The transplant program will give a direct phone number for its coordinator or on-call team; use it rather than waiting for the next appointment.
Call the care team promptly, or seek emergency care, for any of the following, which are red flags at any stage of the transplant journey:
- A temperature at or above the threshold the team has specified, or chills and shaking, since fever during low blood counts can signal a serious infection.
- New bleeding that does not stop, blood in urine or stool, or widespread small purple spots on the skin.
- Shortness of breath, chest pain or a racing heartbeat.
- Severe or persistent diarrhea, especially with abdominal pain, after transplant.
- A new rash, particularly on the palms, soles, face or trunk, or yellowing of the skin or eyes, which can be early signs of GVHD.
- Confusion, severe headache, a seizure, or a sudden change in alertness.
- Inability to keep down fluids or medicines for more than a few hours.
- Redness, swelling or discharge around a central line.
Donors have their own list. After collection, a donor should contact the collection center for fever, worsening pain not relieved by the measures advised, signs of infection at a puncture site, persistent dizziness, or any symptom that worries them. Growth factor injections can cause bone aches and, rarely, spleen enlargement; sudden left-sided abdominal or shoulder pain in a donor during or after those injections needs urgent assessment.
Emotional strain is also worth raising. The waiting period, the possibility that a relative will not match, and the responsibility donors feel are all recognized sources of distress, and transplant programs have social workers and psychologists for exactly this reason. Every decision about proceeding, pausing or changing the plan rests with the treating team, informed by what the patient and family report.
Frequently asked questions
What is HLA typing for a stem cell transplant?
HLA typing is a DNA test that identifies which versions of the human leukocyte antigen genes a person carries. These genes produce surface proteins that the immune system uses to tell self from non-self. For a stem cell transplant, the patient’s HLA result is compared with potential donors so the team can choose the closest match and reduce the risk of rejection and graft-versus-host disease.
HLA typing vs blood typing: do a donor and recipient need the same blood group?
No. Stem cell donors and recipients do not need matching blood groups, because HLA, not ABO, drives immune compatibility for marrow. Blood typing looks at antigens on red cells, which carry almost no HLA. After a successful transplant the patient’s blood group gradually changes to the donor’s. Teams plan around an ABO mismatch with laboratory and transfusion steps; it is manageable rather than disqualifying.
What is a half match stem cell transplant?
A half-match, or haploidentical, transplant uses a donor who shares one of the patient’s two inherited HLA haplotypes, typically a parent, child or sibling. Newer approaches to preventing graft-versus-host disease, including a timed chemotherapy medicine given after infusion or laboratory removal of certain T cells, have made this an established option when no fully matched donor is available. The transplant team weighs it against other donor types case by case.
Why is HLA matching for bone marrow transplant harder for some ancestries?
HLA gene versions cluster within populations, and volunteer registries have historically enrolled fewer people from some backgrounds. A large US registry analysis found the chance of an 8/8 matched adult donor was around 75% for patients of white European ancestry and under 20% for Black patients. Mixed ancestry lowers the odds further. Half-matched relatives and cord blood help close this gap, and registries actively recruit under-represented groups.
Who is not a good candidate for a donor stem cell transplant?
Teams usually defer or recommend other treatment when there is an active uncontrolled infection, disease that is not yet adequately controlled, or heart, lung, liver or kidney function too limited to tolerate conditioning. Lack of a suitable donor at that moment, or an insufficient support network for months of close follow-up, can also lead to waiting. These are revisited decisions made by the multidisciplinary transplant team.
What is the cost of HLA testing?
No single figure applies. HLA typing for a patient and immediate family is normally arranged through the transplant program and handled with the patient’s insurer or health system, while registry typing for volunteers is generally free to the donor. Coverage rules differ by country and plan. The transplant coordinator or financial counselor attached to the program is the right person to ask about what applies in a specific case.
Does a liver transplant need HLA typing?
Routine HLA matching is not required for liver transplantation. Livers are allocated mainly on blood group compatibility, size and medical urgency, because the liver tolerates immune attack relatively well and the organ shortage makes waiting for an HLA match impractical. Kidney transplants use HLA matching and antibody screening more heavily. Stem cell transplants depend on HLA most of all, because the graft is a complete immune system.
What cell types express HLA?
HLA class I molecules (A, B, C) are found on nearly all nucleated cells, including skin, gut lining, liver and every white blood cell. HLA class II molecules (DR, DQ, DP) appear mainly on antigen-presenting cells such as dendritic cells, B cells and macrophages. Mature red blood cells and platelets carry little or no HLA, which is why transfusions are matched by ABO and Rh instead.
Can a perfect HLA match still cause graft-versus-host disease?
Yes. Even a 10/10 match leaves differences in many minor histocompatibility antigens outside the HLA genes, so graft-versus-host disease can still occur. Close matching lowers the risk and severity substantially but does not eliminate it, which is why matched transplants still use immune-modulating medicines for months afterward. The care team monitors skin, gut and liver, the organs most often affected, throughout recovery.
How long does it take to find a stem cell donor?
It varies widely. Typing immediate family can be completed quickly, and preliminary registry searches often return potential matches within days, but confirmatory high-resolution typing, donor medical screening and scheduling take longer. Patients with common HLA combinations tend to have shorter searches; those with rare or mixed-ancestry profiles may need a half-matched relative or cord blood. The transplant coordinator can give a realistic estimate for an individual case.
This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.
More from the Blog
Bladder Tumor Resection (TURBT) Step by Step: Removing the Tumor Through the Urethra
A TURBT (transurethral resection of bladder tumor) is a procedure in which a surgeon passes a thin telescope through the urethra into the bladder,…
What Happens During a Therapeutic Apheresis Session: Access, the Circuit and Return
During a therapeutic plasma exchange session, blood leaves the body through a needle or catheter, passes through a machine that separates the liquid plasma…
Questions to Ask Your Gynecologic Oncologist Before Vulvar Cancer Treatment
Before vulvar cancer treatment, ask your gynecologic oncologist what type and stage of cancer you have, whether surgery, radiation, chemotherapy or a combination is…
Your First Cancer Rehabilitation Visit: What to Bring and Which Daily Tasks to Write Down
For a first cancer rehab appointment, bring your treatment summary, a current list of medicines and supplements, any recent scan or lab reports, comfortable…
Inside a Breast Cancer Tumor Board: Who Sits at the Table and What Gets Decided
A breast cancer tumor board is a scheduled meeting where a surgeon, medical oncologist, radiation oncologist, radiologist and pathologist, often with a nurse navigator,…
Medicines After a Bone Marrow Transplant: Anti-Rejection, Antivirals and What Blood Tests Track
After a bone marrow (stem cell) transplant, most people take a combination of immunosuppressants to prevent graft-versus-host disease, plus preventive antiviral, antifungal and antibiotic…






